Changes coming to preferred products for pegfilgrastim (reference product Neulasta®) for commercial and Medicare Advantage members, starting April 1

For dates of service on or after April 1, 2022, we're making the following changes to the medications designated as preferred and nonpreferred pegfilgrastim products (reference product: Neulasta):

This change affects select Blue Cross Blue Shield of Michigan commercial members, all Blue Care Network commercial members, all Medicare Plus BlueSM members and all BCN AdvantageSM members. (See the “Additional information for Blue Cross commercial members” section of this message for more information.)

Here's what you need to know when prescribing these products:

Submitting requests for prior authorization

Here's how to submit prior authorization requests for preferred products and for nonpreferred products.

Additional information for Blue Cross commercial members

The requirements outlined in this message apply as follows:

List of requirements

See the following lists to view requirements for these products.

We'll update the lists to reflect these changes prior to the effective date.

*Clicking this link means that you’re leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we’re not responsible for its content.

Posted: January 2022
Lines of business: Blue Cross Blue Shield of Michigan and Blue Care Network